172 related articles for article (PubMed ID: 35135736)
1. The Relationship Between PSA and Total Testosterone Levels in Men With Prostate Cancer.
Flores JM; Bernie HL; Miranda E; Nascimento B; Schofield E; Benfante N; Carlsson S; Mulhall JP
J Sex Med; 2022 Mar; 19(3):471-478. PubMed ID: 35135736
[TBL] [Abstract][Full Text] [Related]
2. Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States.
Chen T; Li S; Eisenberg ML
J Sex Med; 2021 Aug; 18(8):1346-1353. PubMed ID: 34303630
[TBL] [Abstract][Full Text] [Related]
3. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months.
Morgentaler A; Benesh JA; Denes BS; Kan-Dobrosky N; Harb D; Miller MG
J Sex Med; 2014 Nov; 11(11):2818-25. PubMed ID: 25131184
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
7. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
[TBL] [Abstract][Full Text] [Related]
8. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
9. The relationship of testosterone to prostate-specific antigen in men with sexual dysfunction.
Corona G; Boddi V; Lotti F; Gacci M; Carini M; De Vita G; Sforza A; Forti G; Mannucci E; Maggi M
J Sex Med; 2010 Jan; 7(1 Pt 1):284-92. PubMed ID: 19912506
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD
J Androl; 2002; 23(6):922-6. PubMed ID: 12399540
[TBL] [Abstract][Full Text] [Related]
11. Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy.
García-Cruz E; Huguet J; Piqueras M; Márquez MP; Peri L; Izquierdo L; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
World J Urol; 2012 Jun; 30(3):361-5. PubMed ID: 21833558
[TBL] [Abstract][Full Text] [Related]
12. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
Rhoden EL; Morgentaler A
J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
[TBL] [Abstract][Full Text] [Related]
13. Racial differences in hypogonadal improvement and prostate-specific antigen levels in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
Int Braz J Urol; 2010; 36(6):700-7; discussion 707-9. PubMed ID: 21176276
[TBL] [Abstract][Full Text] [Related]
14. The role of serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk.
Gurbuz C; Canat L; Atis G; Guner B; Caskurlu T
Kaohsiung J Med Sci; 2012 Dec; 28(12):649-53. PubMed ID: 23217356
[TBL] [Abstract][Full Text] [Related]
15. Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial.
Cunningham GR; Ellenberg SS; Bhasin S; Matsumoto AM; Parsons JK; Preston P; Cauley JA; Gill TM; Swerdloff RS; Wang C; Ensrud KE; Lewis CE; Pahor M; Crandall JP; Molitch ME; Cifelli D; Basaria S; Diem SJ; Stephens-Shields AJ; Hou X; Snyder PJ
J Clin Endocrinol Metab; 2019 Dec; 104(12):6238-6246. PubMed ID: 31504596
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk.
Morote J; Planas J; Ramirez C; Gómez E; Raventós CX; Placer J; Catalán R; de Torres IM
BJU Int; 2010 Feb; 105(4):481-4. PubMed ID: 19681902
[TBL] [Abstract][Full Text] [Related]
17. Serum PSA as a predictor of testosterone deficiency.
Rastrelli G; Corona G; Vignozzi L; Maseroli E; Silverii A; Monami M; Mannucci E; Forti G; Maggi M
J Sex Med; 2013 Oct; 10(10):2518-28. PubMed ID: 23859334
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
[TBL] [Abstract][Full Text] [Related]
19. Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mL.
Kravchick S; Peled R; Dorfman D; Agulansky L; Ben-Dor D; Cytron S
Urology; 2005 Sep; 66(3):542-6. PubMed ID: 16140074
[TBL] [Abstract][Full Text] [Related]
20. Pathology grade influences competing mortality risks in elderly men with prostate cancer.
Alam MU; Kumar J; Norez D; Tanneru K; Jazayeri SB; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Gautam S; Balaji KC
Urol Oncol; 2021 Aug; 39(8):493.e1-493.e7. PubMed ID: 33353870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]